<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00426348</url>
  </required_header>
  <id_info>
    <org_study_id>GPPH200603</org_study_id>
    <nct_id>NCT00426348</nct_id>
  </id_info>
  <brief_title>A Study of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy</brief_title>
  <official_title>A Prospective Randomized, Controlled, Double Blinded Trial of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangdong General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      a statement of the study hypothesis:the effect of valsartan in patients with IgA nephropathy
      have been proved,and the efficacy of probucol in combination with valsartan is to be proved
      in patients with IgA nephropathy.

      This is a prospective randomized controlled, double blinded pilot study to identify the
      efficacy of probucol in combination with valsartan in patients with IgA nephropathy. The
      renal function deterioration will be the primary outcome studied. The expected study duration
      will be 36 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>urinary protein loss whithin 24 hours</measure>
    <time_frame>2-3years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>renal function(serum Crea or eGFR) deterioration</measure>
    <time_frame>2-3years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Glomerulonephritis</condition>
  <condition>IGA Nephropathy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In arm 1,Valsartan(80-160mg/day) is given to patients in combination with Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Valsartan(80-160mg/day) + Probucol(750mg/day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan</intervention_name>
    <description>Valsartan (80-160mg/day)</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Probucol</intervention_name>
    <description>Probucol (750mg/day)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who fulfill the clinical and pathological criteria for IgA nephropathy

          -  Age: 18-60 years

          -  Renal biopsy diagnostic for IgA nephropathy based on immunohistologic staining for IgA
             that is greater than or equal to staining for IgG and IgM

          -  Urinary protein excretion rate is within the range of 1-2.5g/day

          -  Serum creatinine &lt;265.2umol/L at the time of randomization

        Exclusion Criteria:

          -  Patients who refuse to be randomized for treatment

          -  Patients who prefer treatment with conventional agents

          -  Patients who are pregnant or plan for pregnancy

          -  Patients who are pathologically proven severely or diffusely proliferative IgA
             nephropathy or crescent glomerulonephritis with &gt;= 50% segmental involvement of the
             glomeruli and should be treated with other agents,such as immunosuppressive agents or
             steroid

          -  Clinical and histologic evidence of:

               -  systemic lupus erythematosus

               -  Henoch-Schonlein purpura

               -  cirrhosis

               -  chronic active liver disease

               -  hepatitis B

               -  hepatitis C

               -  severe chronic diarrhea

               -  active peptic ulcer disease

               -  HIV

               -  acute renal failure

               -  malignant hypertension

               -  severe heart diseases

               -  malignant tumor

               -  any systemic infection

               -  pregnancy

               -  Known contraindication to the administration of probucol and valsartan
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Shi, PhD,MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nephrology Dept.,Guangdong General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Guangdong General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2007</study_first_submitted>
  <study_first_submitted_qc>January 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2007</study_first_posted>
  <last_update_submitted>August 27, 2013</last_update_submitted>
  <last_update_submitted_qc>August 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangdong General Hospital</investigator_affiliation>
    <investigator_full_name>Wei Shi</investigator_full_name>
    <investigator_title>Director of renal division of Guangdong General Hospital</investigator_title>
  </responsible_party>
  <keyword>IgA nephropathy</keyword>
  <keyword>probucol</keyword>
  <keyword>valsartan</keyword>
  <keyword>treatment</keyword>
  <keyword>antioxidant</keyword>
  <keyword>IGA nephropathyï¼ša kind of glomerulonephritis,which IgA is the dominant immunodeposit in mesangial areas</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
    <mesh_term>Glomerulonephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Antioxidants</mesh_term>
    <mesh_term>Probucol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

